Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07308132 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

StatusRecruiting
PhasePhase 1
Started2026-01-20
View on ClinicalTrials.gov ↗
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.

Amendment history 6 changes detected by DataLookout

2026-09-11
Primary endpoint(s) modified
WasPart 1 and 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity for JNJ-95566692 (Arm A) And in Combination With JNJ-87801493 (Arm B), Part 1: Number of Participants with Dose Limiting Toxicity (DLTs) for JNJ-95566692 (Arm A) And in Combination With JNJ-87801493 (Arm B)
NowPart 1 and 2: Number of Participants with Adverse Events (AEs) And Serious Adverse Events (SAEs) by Severity, Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)
2026-09-11
Enrollment increased: 130 → 340 participants
2026-09-11
Trial arms changed: 2 → 7
2026-09-11
Completion pushed: 2028-08-31 → 2029-10-31
2026-09-11
Interventions modified
2026-07-11
Trial sites expanded: 9 → 19 locations
Trial Details
NCT Number NCT07308132
Lead Sponsor Janssen Research & Development, LLC
Conditions Lymphoma, Non-Hodgkin
Enrollment 340 participants
Start Date 2026-01-20
Primary Completion 2028-08-31 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-10